147 search results for: patient burden
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
Piecing Together the Puzzle in Patients With EoE
In this hypothetical EoE patient case, learn about the different disease domains that are important in seeing the complete patient picture in EoE.
Bullous Pemphigoid: Exploring New Frontiers
Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
Assessing EoE: Assessing Symptoms in Patients With EoE
Join Dr. Nirmala Gonsalves as she reviews symptoms of EoE and tools to assess symptoms in patients with EoE.
Assessing EoE: Monitoring Patients With EoE in Clinical Practice
Hear Dr. Ulrike von Arnim discuss the expert recommendations for monitoring patients with EoE in routine clinical practice.
Assessing EoE: Measuring Quality of Life in Patients With EoE
Join Dr. Nirmala Gonsalves as she reviews some of the tools to assess quality-of-life outcomes in patients with EoE.
European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg
Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
Patient Case - The Value of an Interdisciplinary Team in EoE Patient Care
Chapter from Interdisciplinary Care of Patients with EoE: Experts Offer Food for Thought video: Focuses on the importance of an interdisciplinary team for EoE management.
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Patient Case - The Value of a Complete Pathology Report in EoE
Chapter from Interdisciplinary Care of Patients with EoE: Experts Offer Food for Thought video: Focuses on the value of different aspects of histology beyond eosinophil count and the importance of multidimensional assessment of EoE
